Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”The Immunogenicity Challenge in Next-Generation Gene Therapy Dr. Guy Young‘s ASH2025 session “Deconstructing Gene Therapy in Haemophilia” highlighted a critical tension: the ASC618 Phase 1/2 trial shows both patients of the first cohort dosed with 2e12 vg/kg developed high-titer inhibitors to the ET3 transgene.
What is ASC618?
ASC618 uses ET3—a bioengineered BDD-FVIII chimera incorporating porcine sequences (A1/A3 domains) designed to enhance secretion 10–100x over native human FVIII, enabling lower doses.
The Problem:
These porcine residues could have acted as potent neo-antigens, breaking tolerance even in previously naive patients.
Both are now on emicizumab.
Predictive immunogenicity modeling for non-native constructs needs strengthening before clinical translation.”
All from ASH25 featured in Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers